Testing Stapokibart for Eczema in Children Ages 2 to 11
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests an experimental medication (Stapokibart) for children ages 2 to 11 with moderate-to-severe eczema that hasn't improved with topical creams. The goal is to see if the new treatment can help control their symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 2 and 11 years old.
- They have moderate-to-severe eczema that hasn't responded well to prescription creams.
- They have not received Stapokibart before.
- They have not used certain other eczema medicines (like Dupixent) in the past few weeks.
- They are not planning major surgery during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called Stapokibatrt in children with atopic dermatitis (eczema). It is for kids who already completed the main study and may help manage their skin condition.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This study tests a new moisturizing product (RV4421B) for people with mild to moderate atopic dermatitis (eczema). Participants will use the product along with their usual steroid cream for 12 weeks to see how well it works and if it’s safe for different ages, from babies to adults.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.